Non-celiac gluten sensitivity triggers gut dysbiosis, neuroinflammation, gut-brain axis dysfunction, and vulnerability for dementia

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 1, 2015, Pages 110-131

  Daulatzai, Mak A ^a  

^a The University of Melbourne   (Australia)

Author keywords

Axis; Cytokines; Dysbiosis; Gut brain; Lipopolysaccharide; Microbiota; Neuroinflammation; Non celiac gluten sensitivity; Oxidative nitrosative stress; Vagus nerve stimulation

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID A PROTEIN; BUNGAROTOXIN RECEPTOR; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CYCLOOXYGENASE 2; EXCITATORY AMINO ACID TRANSPORTER 1; GAMMA INTERFERON; GLIADIN ANTIBODY; GLUTEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AGING; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ARTICLE; BRAIN DYSFUNCTION; CELIAC DISEASE; CEREBELLAR ATAXIA; COGNITIVE DEFECT; CYTOKINE RELEASE; DYSBIOSIS; ENDOTOXEMIA; EXCITATORY POSTSYNAPTIC POTENTIAL; FAT INTAKE; HIPPOCAMPUS; HOST PATHOGEN INTERACTION; HUMAN; INFLAMMATORY INFILTRATE; INTESTINE FLORA; INTESTINE FUNCTION DISORDER; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; NERVOUS SYSTEM INFLAMMATION; NITROSATIVE STRESS; NON CELIAC GLUTEN SENSITIVITY; NONHUMAN; NUTRITIONAL INTOLERANCE; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SLEEP DISORDERED BREATHING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VAGUS NERVE STIMULATION; ANIMAL; BRAIN; CHEMICALLY INDUCED; DEMENTIA; ENCEPHALITIS; GASTROINTESTINAL TRACT;

ANIMALS; BRAIN; DEMENTIA; DYSBIOSIS; ENCEPHALITIS; GASTROINTESTINAL TRACT; GLUTENS; HUMANS;

EID: 84924124703     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150202152436     Document Type: Article

References (378)

1. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136: 65-80.
2. Jones RM, Luo L, Ardita CS, et al. Symbiotic lactobacilli stimulate gut epithelial proliferation via Nox-mediated generation of reactive oxygen species. EMBO J 2013; 32: 3017-28.
3. Zoetendal EG, Vaughan EE, de Vos WM. A microbial world within us. Mol Microbiol 2006; 59: 1639-50.
4. Vipperla K, O'Keefe SJ. The microbiota and its metabolites in colonic mucosal health and cancer risk. Nutr Clin Pract 2012; 27: 624-35.
5. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 2009; 41: 850-3.
6. Ducrotté P. Irritable bowel syndrome: from the gut to the brain-gut. Gastroenterol Clin Biol 2009; 33: 703-12.
7. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 17: 2011; 252-66.
8. Greiner T, Bäckhed F Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol Metab 2011; 22: 117-23.
9. Bäckhed F. Host responses to the human microbiome. Nutr Rev 2012; 70: S14-7.
10. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701-12.
11. Bull-Otterson L, Feng W, Kirpich I, et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One 2013; 8: e53028.
12. Björklund M, Ouwehand AC, Forssten SD, et al. Gut microbiota of healthy elderly NSAID users is selectively modified with the administration of Lactobacillus acidophilus NCFM and lactitol. Age 2012; 34: 987-99.
13. Zhao J, Fox M, Cong Y, et al. Lactose intolerance in patients with chronic functional diarrhoea: the role of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2010; 31: 892-900.
14. Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci 2013; 36: 305-12.
15. Barbara G, Zecchi L, Barbaro R, et al. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol 2012; 46: S52-5.
16. Hughes PA, Zola H, Penttila IA, et al. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol 2013; 108: 1066-74.
17. Bercik P, Park AJ, Sinclair D, et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil 2011; 23: 1132-9.
18. Zipser RD, Farid M, Baisch D, Patel B, Patel D. Physician awareness of celiac disease: a need for further education. J Gen Intern Med 2005; 20: 644-6.
19. Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 2012; 4: 1095-19.
20. Volta U, De Giorgio R. New understanding of gluten sensitivity. Nat Rev Gastroenterol Hepatol 2012; 9: 295-9.
21. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol 2004; 61: 668-72.
22. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr 2006; 83: 470S-4S.
23. Churchill L, Taishi P, Wang M, et al. Brain distribution of cytokine mRNA induced by systemic administration of interleukin-1beta or tumor necrosis factor alpha. Brain Res 2006; 1120: 64-73.
24. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007; 7: 161-7.
25. Hirose Y, Imai Y, Nakajima K, et al. Glial conditioned medium alters the expression of amyloid precursor protein in SH-SY5Y neuroblastoma cells. Biochem Biophys Res Commun 1994; 198: 504-9.
26. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13: 63-8.
27. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992; 89: 10075-8.
28. Parachikova A, Agadjanyan MG, Cribbs DH, et al. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging 2007; 28: 1821-33.
29. Comim CM, Barichello T, Grandgirard D, et al. Caspase-3 mediates in part hippocampal apoptosis in sepsis. Mol Neurobiol 2013; 47: 394-8.
30. Hoozemans JJ, Rozemuller AJ, van Haastert ES, Eikelenboom P, van Gool WA. Neuroinflammation in Alzheimer's disease wanes with age. J Neuroinflammation 2011; 8: 171.
31. Zhu B, Dong Y, Xu Z, et al. Sleep disturbance induces neuroinflammation and impairment of learning and memory. Neurobiol Dis 2012; 48: 348-55.
32. Liu X, Wu Z, Hayashi Y, Nakanishi H. Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation. Neuroscience 2012; 216: 133-42.
33. Dinel AL, André C, Aubert A, et al. Cognitive and emotional alterations are related to hippocampal inflammation in a mouse model of metabolic syndrome. PLoS One 2011; 6: e24325.
34. Huxtable AG, Smith SM, Vinit S, Watters JJ, Mitchell GS. Systemic LPS induces spinal inflammatory gene expression and impairs phrenic long-term facilitation following acute intermittent hypoxia. J Appl Physiol 2013; 114: 879-87.
35. Howe CL, Lafrance-Corey RG, Sundsbak RS, Lafrance SJ. Inflammatory monocytes damage the hippocampus during acute picornavirus infection of the brain. J Neuroinflammation 2012; 9: 50.
36. Field RH, Gossen A, Cunningham C. Prior pathology in the basal forebrain cholinergic system predisposes to inflammation-induced working memory deficits: reconciling inflammatory and cholinergic hypotheses of delirium. J Neurosci 2012; 32: 6288-94.
37. Koning F, Gilissen L, Wijmenga C. Gluten: a two-edged sword. Immunopathogenesis of celiac disease. Springer Semin Immunopathol 2005; 27: 217-32.
38. Ciaccio EJ, Lewis SK, Green PH. Detection of villous atrophy using endoscopic images for the diagnosis of celiac disease. Dig Dis Sci 2013; 58: 1167-9.
39. Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology 2011; 141: 1187-93.
40. Visakorpi JK, Mäki M. Changing clinical features of coeliac disease. Acta Paediatr Suppl 1994; 395: 10-13.
41. Abdulkarim AS, Burgart LJ, See J, Murray JA. Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol 2002; 97: 2016-21.
42. Ferch CC, Chey WD. Irritable bowel syndrome and gluten sensitivity without celiac disease: separating the wheat from the chaff. Gastroenterology 2012; 142: 664-66.
43. Aziz I, Sanders DS. Emerging concepts: from coeliac disease to non-coeliac gluten sensitivity. Proc Nutr Soc 2012; 71: 576-80.
44. Carroccio A, Mansueto P, Iacono G, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol 2012; 107: 1898-906.
45. Lundin KE, Alaedini A. Non-celiac gluten sensitivity. Gastrointest Endosc Clin N Am 2012; 22: 723-34.
46. Verdu EF, Huang X, Natividad J, Lu J, Blennerhassett PA, David CS, McKay DM, Murray JA. Gliadin-dependent neuromuscular and epithelial secretory responsesin gluten-sensitive HLA-DQ8 transgenic mice. Am J Physiol Gastrointest Liver Physiol 2008; 294: G217-25.
47. Hadjivassiliou M, Grünewald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet 1998; 352: 1582-85.
48. Nilsen EM, Jahnsen FL, Lundin KE, et al. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 1998: 115: 551-63.
49. Brottveit M, Beitnes AC, Tollefsen S, et al. Mucosal cytokine response after short-term gluten challenge inceliac disease and non-Celiac gluten sensitivity. Am J Gastroenterol 2013; 108: 842-50.
50. Sapone A, Lammers KM, Casolaro V, et al. Divergence of gut permeability and mucosal immune gene expression in two glutenassociated conditions: celiac disease and gluten sensitivity. BMC Med 2011; 9: 23.
51. Dezi R, Niveloni S, Sugai E, et al. Gluten sensitivity inthe rectal mucosa of first-degree relatives of celiac disease patients. Am J Gastroenterol 1997; 92: 1326-30.
52. Lock RJ, Pengiran Tengah DS, Unsworth DJ, Ward JJ, Wills AJ. Ataxia, peripheral neuropathy, and anti-gliadin antibody. Guilt by association? J Neurol Neurosurg Psychiatry 2005; 76: 1601-3.
53. Catassi C, Bai JC, Bonaz B, et al. Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients 2013; 5: 3839-53.
54. Lock RJ, Tengah DP, Williams AJ, et al. Cerebellar ataxia, peripheral neuropathy, "gluten sensitivity" and anti-neuronal autoantibodies. Clin Lab 2006; 52: 589-92.
55. Bhatia KP, Brown P, Gregory R, et al. Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Brain 1995; 118: 1087-93.
56. Bushara KO. Neurologic presentation of celiac disease. Gastroenterology 2005; 128: S92-7.
57. Bushara KO, Goebel SU, Shill H, Goldfarb LG, Hallett M. Gluten sensitivity in sporadic and hereditary cerebellar ataxia. Ann Neurol 2001; 49: 540-3.
58. Bürk K, Bösch S, Müller CA, et al. Sporadic cerebellar ataxia associated with gluten sensitivity. Brain 2001; 124: 1013-9.
59. Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology 2001; 121: 1329-38.
60. Wahnschaffe U, Schulzke JD, Zeitz M, Ullrich R. Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 844-50.
61. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J 1991; 5: 3071-7.
62. Verdu EF, Huang X, Natividad J, et al. Gliadin-dependent neuromuscular and epithelial secretory responses in glutensensitive HLA-DQ8 transgenic mice. Am J Physiol Gastrointest Liver Physiol 2008; 294: G217-25.
63. Black KE, Murray JA, David CS. HLA-DQ determines the response to exogenous wheat proteins: a model of gluten sensitivity in transgenic knockout mice. J Immunol 2002; 169: 5595-600.
64. Senger S, Maurano F, Mazzeo MF, et al. Identification of immunodominant epitopes of a-gliadin in HLA-DQ8 transgenic mice following oral immunization. J Immunol 2005; 175: 8087-95.
65. Zanelli E, Krco CJ, Baisch JM, Cheng S, David CS. Immune response of HLA-DQ8 transgenic mice to peptides from the third hypervariable region of HLA-DRB1 correlates with predisposition to rheumatoid arthritis. Proc Natl Acad Sci USA 1996; 93: 1814-9.
66. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-9.
67. Macpherson AJ, Slack E. The functional interactions of commensal bacteria with intestinal secretory IgA. Curr Opin Gastroenterol 2007; 23: 673-8.
68. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008; 453: 620-5.
69. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-5.
70. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbederived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-50.
71. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010; 31: 817-44.
72. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 2011; 108: 16050-5.
73. Gareau MG, Wine E, Rodrigues DM, et al. Bacterial infection causes stress-induced memory dysfunction in mice. Gut 2011; 60: 307-17.
74. Neufeld KA, Kang N, Bienenstock J, Foster JA. Effects of intestinal microbiota on anxiety-like behavior. Commun Integr Biol 2011; 4: 492-4.
75. Sugaya N, Nomura S, Shimada H. Relationship between cognitive factors and anxiety in individuals with irritable bowel syndrome. Int J Behav Med 2012; 19: 308-15.
76. Wu JC. Psychological Co-morbidity in Functional Gastrointestinal Disorders: Epidemiology, Mechanisms and Management. J Neurogastroenterol Motil 2012; 18: 13-8.
77. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea. Am J Physiol Gastrointest Liver Physiol 2012; 303: G1262-9.
78. Collins S, Verdu E, Denou E, Bercik P. The role of pathogenic microbes and commensal bacteria in irritable bowel syndrome. Dig Dis 2009; 27(Suppl 1): 85-9.
79. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 2009; 41: 850-3.
80. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012; 10: 735-42.
81. Van Oudenhove L, Demyttenaere K, Tack J, Aziz QB. Central nervous system involvement in functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004; 18: 663-80.
82. Barbara G, De Giorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 1-9.
83. Barbara G. Mucosal barrier defects in irritable bowel syndrome. Who left the door open? Am J Gastroenterol 2006; 101: 1295-8.
84. Barbara G, Zecchi L, Barbaro R, et al. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol 2012; 46(Suppl): S52-5.
85. Rodes L, Khan A, Paul A, et al. Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol 2013; 23: 518-26.
86. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndromediarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013; 144: 903-11.
87. Bauer H, Paronetto F, Burns WA, Einheber A. The enhancing effect of the microbial flora on macrophage function and the immune response. A study in germ free mice. J Exp Med 1966; 123: 1013-24.
88. Tsuda M, Hosono A, Yanagibashi T, et al. Intestinal commensal bacteria promote T cell hyporesponsiveness and down-regulate the serum antibody responses induced by dietary antigen. Immunol Lett 2010; 132: 45-52.
89. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008; 1: 11-22.
90. Beutler B, Hoebe K, Du X, Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003; 74: 479-85.
91. Tobias PS, Soldau K, Gegner JA, Mintz D, Ulevitch RJ. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem 1995; 270: 10482-8.
92. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
93. Guigoz Y, Doré J, Schiffrin EJ. The inflammatory status of old age can be nurtured from the intestinal environment. Curr Opin Clin Nutr Metab Care 2008; 11: 13-20.
94. Zahorska-Markiewicz B, Janowska J, Olszanecka-Glinianowicz M, Zurakowski A. A Serum concentrations of TNF-α and soluble TNF-α receptors in obesity. Int J Obes Relat Metab Disord 2000; 24: 1392-5.
95. El-Wakkad A, Hassan N-M, Sibaii H, El-Zayat SR. Proinflammatory, anti-inflammatory cytokines and adiponkines in students with central obesity. Cytokine 2013; 61: 682-7.
96. Nov O, Shapiro H, Ovadia H, et al. Interleukin-1β regulates fatliver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. PLoS One 2013; 8: e53626.
97. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997; 389: 610-4.
98. Shanab AA, Scully P, Crosbie O, et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with tolllike receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011; 56: 1524-34.
99. Neal MD, Leaphart C, Levy R, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006; 176: 3070-9.
100. Cani PD, Delzenne NM. Involvement of the gut microbiota in the development of low grade inflammation associated with obesity: focus on this neglected partner. Acta Gastroenterol Belg 2010; 73: 267-9.
101. Moreira AP, Texeira TF, Ferreira AB, Peluzio MC, Alfenas RC. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr 2012; 108: 801-9.
102. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-72.
103. Hosoi T, Okuma Y, Nomura Y. Electrical stimulation of afferent vagus nerve induces IL-1beta expression in the brain and activates HPA axis. Am J Physiol Regul Integr Comp Physiol 2000; 279: R141-7.
104. Hansen MK, Taishi P, Chen Z, Krueger JM. Vagotomy blocks the induction of interleukin-1beta (IL-1beta) mRNA in the brain of rats in response to systemic IL-1beta. J Neurosci 1998; 18: 2247-53.
105. Enck P, Zimmermann K, Rusch K, et al. The effects of ageing on the colonic bacterial microflora in adults. Z Gastroenterol 2009; 47: 653-8.
106. Woodmansey EJ. Intestinal bacteria and ageing. J Appl Microbiol 2007; 102: 1178-86.
107. Guigoz Y, Doré J, Schiffrin EJ. The inflammatory status of old age can be nurtured from the intestinal environment. Curr Opin Clin Nutr Metab Care 2008; 11: 13-20.
108. Hébuterne X. Gut changes attributed to ageing: effects on intestinal microflora. Curr Opin Clin Nutr Metab Care 2003; 6: 49-54.
109. Biagi E, Nylund L, Candela M, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010; 5: e10667.
110. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009; 137: 1716-24.
111. Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94: 58-65.
112. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
113. Laugerette F, Vors C, Peretti N, Michalski MC. Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. Biochimie 2011; 93: 39-45.
114. Amar J, Burcelin R, Ruidavets JB, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008; 87: 1219-23.
115. de La Serre CB, Ellis CL, Lee J, et al. Propensity to high-fat dietinduced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010; 299: G440-8.
116. Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One 2012; 7: e47713.
117. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013; 34: 39-58.
118. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718-23.
119. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008; 3: 213-23.
120. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-4.
121. Diamant M, Blaak EE, de Vos WM. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev 2011; 12: 272-81.
122. Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med 2011; 62: 361-80.
123. Burcelin R. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut 2012; 61: 543-53.
124. de Wit N, Derrien M, Bosch-Vermeulen H, et al. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am J Physiol Gastrointest Liver Physiol 2012; 303: G589-99.
125. Fava F, Gitau R, Griffin BA, et al. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. Int J Obes (Lond) 2013; 37: 216-23.
126. Murphy EF, Cotter PD, Healy S, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010; 59: 1635-42.
127. Cani PD, Delzenne NM, Amar J, Burcelin R. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol Biol 2008; 56: 305-9.
128. Roncon-Albuquerque R Jr, Moreira-Rodrigues M, Faria B, et al. Attenuation of the cardiovascular and metabolic complications of obesity in CD14 knockout mice. Life Sci 2008; 83: 502-10.
129. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, et al. Loss-offunction mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007; 56: 1986-98.
130. Delzenne NM, Cani PD. Gut microbiota and the pathogenesis of insulin resistance. Curr Diab Rep 2011; 11: 154-9.
131. Ding S, Chi MM, Scull BP, et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010; 5: e12191.
132. Ding S, Lund PK. Role of intestinal inflammation as an early event in obesity and insulin resistance. Curr Opin Clin Nutr Metab Care 2011; 14: 328-33.
133. De Bandt JP, Waligora-Dupriet AJ, Butel MJ. Intestinal microbiota in inflammation and insulin resistance: relevance to humans. Curr Opin Clin Nutr Metab Care 2011; 14: 334-40.
134. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3: 279-88.
135. Serino M, Luche E, Gres S, et al. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. J Parenter Enteral Nutr 2011; 35: 14S-20S.
136. DiBaise JK, Zhang H, Crowell MD, et al. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008; 83: 460-9.
137. Pataky Z, Bobbioni-Harsch E, Hadengue A, Carpentier A, Golay A. Gut microbiota, responsible for our body weight? Rev Med Suisse 2009; 5: 662-6.
138. Amin PB, Diebel LN, Liberati DM. Dose-dependent effects of ethanol and E. coli on gut permeability and cytokine production. J Surg Res 2009; 157: 187-92.
139. Fleming S, Toratani S, Shea-Donohue T, et al. Pro-and antiinflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol. Alcohol Clin Exp Res 2001; 25: 579-89.
140. Bode C, Bode JC. Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? Alcohol Clin Exp Res 2005; 29: 166S-71S.
141. Mutlu E, Keshavarzian A, Engen P, et al. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009; 33: 1836-46.
142. Bull-Otterson L, Feng W, Kirpich I, et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One 2013; 8: e53028.
143. Qin L, He J, Hanes RN, et al. Increased systemic and brain cytokine production and neuroinflammation by endotoxin following ethanol treatment. J Neuroinflammation 2008; 5: 10.
144. Qin L, Crews FT. Chronic ethanol increases systemic TLR3 agonist-induced neuroinflammation and neurodegeneration. J Neuroinflammation 2012; 9: 130.
145. Zou J, Crews FT. Inflammasome-IL-1β Signaling Mediates Ethanol Inhibition of Hippocampal Neurogenesis. Front Neurosci 2012; 6: 77.
146. Aabakken L, Osnes M. Non-steroidal anti-inflammatory druginduced disease in the distal ileum and large bowel. Scand J Gastroenterol 1989; 163: 48-55.
147. Imaoka H, Ishihara S, Kazumori H, et al. Exacerbation of indomethacin-induced small intestinal injuries in Reg I-knockout mice. Am J Physiol Gastrointest Liver Physiol 2010; 299: G311-9.
148. Keszthelyi D, Dackus GH, Masclee GM, Kruimel JW, Masclee AA. Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study. BMC Gastroenterol 2012; 12: 121.
149. Kerckhoffs AP, Akkermans LM, de Smet MB, et al. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci 2010; 55: 716-23.
150. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-94.
151. Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201.
152. He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 2003; 101: 1572-81.
153. Jijon HB, Madsen KL, Walker JW, Allard B, Jobin C. Serum amyloid A activates NF-kappaB and proinflammatory gene expression in human and murine intestinal epithelial cells. Eur J Immunol 2005; 35: 718-26.
154. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501-23.
155. Ray A, Shakya A, Kumar D, Benson MD, Ray BK. Inflammationresponsive transcription factor SAF-1 activity is linked to the development of amyloid A amyloidosis. J Immunol 2006; 177: 2601-9.
156. Sandri S, Rodriguez D, Gomes E, et al. Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol 2008; 83: 1174-80.
157. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995; 16: 21-6.
158. Yang RZ, Lee MJ, Hu H, et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 2006; 3: e287.
159. Foyn Bruun C, Sletten K, Marhaug G. Mouse serum amyloid A (SAA) proteins isolated by two-dimensional electrophoresis: characterization of isotypes and the effect of separate and combined administrations of cytokines, dexamethasone and lipopolysaccharide (LPS) on serum levels and isotype distribution. Clin Exp Immunol 1998; 111: 231-6.
160. Bartolák-Suki E, Sipe JD, Fine RE, Rosene DL, Moss MB. Serum amyloid A is present in the capillaries and microinfarcts of hypertensive monkey brain: an immunohistochemical study. Amyloid 2000; 7: 111-17.
161. Morrow JF, Stearman RS, Peltzman CG, Potter DA. Induction of hepatic synthesis of serum amyloid A protein and actin. Proc Natl Acad Sci USA 1981; 78: 4718-22.
162. Raynes JG, Eagling S, McAdam KP. Acute phase protein synthesis in hepatoma cells: differential regulation of SAA and haptoglobin by IL-1 and IL-6. Clin Exp Immunol 1991; 83: 488-91.
163. Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P. The role of NF-κB and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by nterleukin-1 and Interleukin-6. J Biol Chem 1993; 268: 25624-31.
164. Xu DZ, Lu Q, Kubicka R, Deitch EA. The effect of hypoxia/reoxygenation on the cellular function of intestinal epithelial cells. J Trauma 1999; 46: 280-5.
165. Diebel LN, Liberati DM, Taub JS, Diglio CA, Brown WJ. Intestinal epithelial cells modulate PMN activation and apoptosis following bacterial and hypoxic challenges. J Trauma 2005; 58: 1126-33.
166. Ding J, Magnotti LJ, Huang Q, et al. Hypoxia combined with Escherichia coli produces irreversible gut mucosal injury characterized by increased intestinal cytokine production and and DNA degradation. Shock 2001; 16: 189-95.
167. Baylor AE, Diebel LN, Liberati DM, et al. The synergistic effects of hypoxia/reoxygenation or tissue acidosis and bacteria on intestinal epithelial cell apoptosis. J Trauma 2003; 55: 241-7.
168. Atkeson A, Jelic S. Mechanisms of endothelial dysfunction in obstructive sleep apnea. Vasc Health Risk Manag 2008; 4: 1327-35.
169. Chalacheva P, Thum J, Yokoe T, O'Donnell CP, Khoo MC. Development of autonomic dysfunction with intermittent hypoxia in a lean murine model. Respir Physiol Neurobiol 2013; 188: 143-51.
170. O'Donnell CP. Metabolic consequences of intermittent hypoxia. Adv Exp Med Biol 2007; 618: 41-9.
171. Kheirandish-Gozal L, Peris E, Wang Y, et al. Lipopolysaccharide-Binding Protein Plasma Levels in Children: Effects of Obstructive Sleep Apnea and Obesity. J Clin Endocrinol Metab 2014; 99: 656-63.
172. Browning KN, Travagli RA. Plasticity of vagal brainstem circuits in the control of gastric function. Neurogastroenterol Motil 2010; 22: 1154-63.
173. Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific response to pathogens. Nat Rev Immunol 2006; 6: 318-28.
174. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway J Clin Invest 2007; 117: 289-96.
175. Rosas-Ballina M, Olofsson PS, Ochani M, et al. Acetylcholinesynthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011; 334: 98-01.
176. Pavlov VA, Parrish WR, Rosas-Ballina M, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun 2009; 23: 41-5.
177. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, Verdu EF, Collins SM. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology 2006; 131: 1122-30.
178. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-8.
179. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-62.
180. Matsunaga K, Klein TW, Friedman H, Yamamoto Y. Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol 2001; 167: 6518-24.
181. Karimi K, Bienenstock J, Wang L, Forsythe P. The vagus nerve modulates CD4+ T cell activity. Brain Behav Immun 2010; 24: 316-23.
182. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nature Rev Neurosci 2012; 13: 701-12.
183. Van der Zanden EP, Boeckxstaens GE, De Jonge WJ. The vagus nerve as a modulator of intestinal inflammation. Neurogastroenterol Motil 2009; 21: 6-17.
184. Hansen MK, Nguyen KT, Goehler LE, et al. Effects of vagotomy on lipopolysaccharide-induced brain interleukin-1beta protein in rats. Auton Neurosci 2000; 85: 119-26.
185. Yilmaz MS, Goktalay G, Millington WR, et al. Lipopolysaccharide-induced hypotension is mediated by a neural pathway involving the vagus nerve, the nucleus tractus solitarius and alpha-adrenergic receptors in the preoptic anterior hypothalamic area. J Neuroimmunol 2008; 203: 39-49.
186. Hansen MK, Taishi P, Chen Z, Krueger JM. Vagotomy blocks the induction of interleukin-1beta (IL-1beta) mRNA in the brain of rats in response to systemic IL-1beta. J Neurosci 1998; 18: 2247-53.
187. Churchill L, Taishi P, Wang M, et al. Brain distribution of cytokine mRNA induced by systemic administration of interleukin-1beta or tumor necrosis factor alpha. Brain Res 2006; 1120: 64-73.
188. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007; 7: 161-7.
189. Zhang R, Miller RG, Gascon R, et al. Circulating endotoxin and systemic immune activation in sporadic Amyotrophic Lateral Sclerosis (sALS). J Neuroimmunol 2009; 206: 121-4.
190. Zhang R, Miller RG, Madison C, et al. Systemic immune system alterations in early stages of Alzheimer's disease. J Neuroimmunol 2013; 256: 38-42.
191. Eikelenboom P, Zhan SS, Van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994; 15: 447-50.
192. Tucsek Z, Toth P, Sosnowska D, et al. Obesity in Aging Exacerbates Blood-Brain Barrier Disruption, Neuroinflammation, and Oxidative Stress in the Mouse Hippocampus: Effects on Expression of Genes Involved in Beta-Amyloid Generation and Alzheimer's Disease. J Gerontol A Biol Sci Med Sci. 2014; 69(10): 1212-26.
193. Gasbarrini G, Ciccocioppo R, De Vitis I, Corazza GR. Coeliac Disease in the Elderly. A multicentre Italian study. Gerontology 2001; 47: 306-10.
194. Lurie Y, Landau DA, Pfeffer J, Oren R. Celiac disease diagnosed in the elderly. J Clin Gastroenterology 2008; 42: 59-61.
195. Hadjivassiliou M, Grünewald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet 1998; 352: 1582-5.
196. Hadjivassiliou M, Chattopadhyay AK, Grünewald RA, et al. Myopathy associated with gluten sensitivity. Muscle Nerve 2007; 35: 443-50.
197. Rashtak S, Rashtak S, Snyder MR, et al. Serology of celiac disease in gluten-sensitive ataxia or neuropathy: role of deamidated gliadin antibody. J Neuroimmunol 2011; 230: 130-4.
198. Hadjivassiliou M, Gibson A, Davies-Jones GA, et al. Does cryptic gluten sensitivity play a part in neurological illness? Lancet 1996; 347: 369-71.
199. Bhatia KP, Brown P, Gregory R, et al. Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Brain 1995; 118: 1087-93.
200. Nanri K, Shibuya M, Taguchi T, Hasegawa A, Tanaka N. Selective loss of Purkinje cells in a patient with anti-gliadin-antibodypositive autoimmune cerebellar ataxia. Diagn Pathol 2011; 6: 14.
201. Bürk K, Melms A, Schulz JB, Dichgans J. Effectiveness of intravenous immunoglobin therapy in cerebellar ataxia associated with gluten sensitivity. Ann Neurol 2001; 50: 827-8.
202. Bürk K, Bösch S, Müller CA, et al. Sporadic cerebellar ataxia associated with gluten sensitivity. Brain 2001; 124: 1013-9.
203. Ihara M, Makino F, Sawada H, et al. Gluten sensitivity in Japanese patients with adult-onset cerebellar ataxia. Intern Med 2006; 45: 135-40.
204. Pellecchia MT, Scala R, Filla A, et al. Idiopathic cerebellar ataxia associated with celiac disease: lack of distinctive neurological features. J Neurol Neurosurg Psychiatry 1999; 66: 32-5.
205. Mittelbronn M, Schittenhelm J, Bakos G, et al. CD8(+)/perforin/granzyme B(+) effector cells infiltrating cerebellum and inferior olives in gluten ataxia. Neuropathology 2010; 30: 92-6.
206. Hu WT, Murray JA, Greenaway MC, Parisi JE, Josephs KA. Cognitive impairment and celiac disease. Arch Neurol 2006; 63: 1440-6.
207. Strick PL, Dum RP, Fiez JA. Cerebellum and nonmotor function. Annu Rev Neurosci 2009; 32: 413-34.
208. Hoffmann LC, Berry SD. Cerebellar theta oscillations are synchronized during hippocampal theta-contingent trace conditioning. Proc Natl Acad Sci USA 2009; 106: 21371-6.
209. Wikgren J, Nokia MS, Penttonen M. Hippocampo-cerebellar theta band phase synchrony in rabbits. Neuroscience 2010; 165: 1538-45.
210. Rochefort C, Lefort JM, Rondi-Reig L. The cerebellum: a new key structure in the navigation system. Front Neural Circuits 2013; 7: 35.
211. Rochefort C, Arabo A, André M, et al. Cerebellum shapes hippocampal spatial code. Science 2011; 334: 385-9.
212. Passot JB, Sheynikhovich D, Duvelle É, Arleo A. Contribution of cerebellar sensorimotor adaptation to hippocampal spatial memory. PLoS One 2012; 7: e32560.
213. Balsters JH, Whelan CD, Robertson IH, Ramnani N. Cerebellum and Cognition: Evidence for the Encoding of Higher Order Rules. Cereb Cortex 2013; 23: 1433-43.
214. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain 1998; 121: 561-79.
215. Martin KL, Blizzard L, Wood AG, et al. Cognitive Function, Gait, and Gait Variability in Older People: A Population-Based Study. J Gerontol A Biol Sci Med Sci 2013; 68: 726-32.
216. Koch G, Mori F, Marconi B, et al. Oliveri M, Caltagirone C. Changes in intracortical circuits of the human motor cortex following theta burst stimulation of the lateral cerebellum. Clin Neurophysiol 2008; 119: 2559-69.
217. Koch G, Brusa L, Carrillo F, et al. Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease. Neurology 2009; 73: 113-9.
218. Di Lorenzo F, Martorana A, Ponzo V, et al. Cerebellar theta burst stimulation modulates short latency afferent inhibition in Alzheimer's disease patients. Front Aging Neurosci 2013; 5: 2.
219. Finkelstein Y, Wolff M, Biegon A. Brain acetylcholinesterase after parathion poisoning: a comparative quantitative histochemical analysis post-mortem. Toxicology 1988; 49: 165-9.
220. Turner JR, Ortinski PI, Sherrard RM, Kellar KJ. Cerebellar nicotinic cholinergic receptors are intrinsic to the cerebellum: implications for diverse functional roles. Cerebellum 2011; 10: 748-57.
221. D'Angelo E, Casali S. Seeking a unified framework for cerebellar function and dysfunction: from circuit operations to cognition. Front Neural Circuits 2012; 6: 116.
222. Okamura N, Funaki Y, Tashiro M, et al. In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease. Br J Clin Pharmacol 2008; 65: 472-9.
223. Larner AJ. The cerebellum in Alzheimer's disease. Dement Geriatr Cogn Disord 1997; 8: 203-9.
224. Sjöbeck M, Englund E. Alzheimer's disease and the cerebellum: a morphologic study on neuronal and glial changes. Dement Geriatr Cogn Disord 2001; 12: 211-8.
225. Stępień T, Wierzba-Bobrowicz T, Lewandowska E, Szpak G. Morphological and quantitative analysis of cerebellar cortical cells in Alzheimer's disease. Folia Neuropathol 2012; 50: 250-60.
226. Mavroudis IA, Fotiou DF, Adipepe LF, et al. Morphological changes of the human purkinje cells and deposition of neuritic plaques and neurofibrillary tangles on the cerebellar cortex of Alzheimer's disease. Am J Alzheimers Dis Other Demen 2010; 25: 585-91.
227. Wegiel J, Wisniewski HM, Dziewiatkowski J, et al. Cerebellar atrophy in Alzheimer's disease-clinicopathological correlations. Brain Res 1999; 818: 41-50.
228. Lasn H, Winblad B, Bogdanovic N. Neuroglia in the inferior olivary nucleus during normal aging and Alzheimer's disease. J Cell Mol Med 2006; 10: 145-56.
229. Mattiace LA, Davies P, Yen SH, Dickson DW. Microglia in cerebellar plaques in Alzheimer's disease. Acta Neuropathol 1990; 80: 493-8.
230. Baldaçara L, Borgio JG, Moraes WA, et al. Cerebellar volume in patients with dementia. Rev Bras Psiquiatr 2011; 33: 122-9.
231. Andersen K, Andersen BB, Pakkenberg B. Stereological quantification of the cerebellum in patients with Alzheimer's disease. Neurobiol Aging 2012; 33: 197. e11-20.
232. Thomann PA, Schlafer C, Seidl U, et al. The cerebellum in mild cognitive impairment and Alzheimer's disease-a structural MRI study. J Psychiatr Res 2008; 42: 1198-02.
233. Möller C, Vrenken H, Jiskoot L, et al. Different patterns of gray matter atrophy in early-and late-onset Alzheimer's disease. Neurobiol Aging 2013; 34: 2014-22.
234. Chen J, Cohen ML, Lerner AJ, Yang Y, Herrup K. DNA damage and cell cycle events implicate cerebellar dentate nucleus neurons as targets of Alzheimer's disease. Mol Neurodegener 2010; 5: 60.
235. Hauser T, Schönknecht P, Thomann PA, et al. Regional cerebral perfusion alterations in patients with mild cognitive impairment and Alzheimer disease using dynamic susceptibility contrast MRI. Acad Radiol 2013; 20: 705-11.
236. McLaren DG, Sreenivasan A, Diamond EL, et al. Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease. Neurodegener Dis 2012; 9: 176-86.
237. Drummond ES, Muhling J, Martins RN, et al. Pathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellum. PLoS One 2013; 8: e59166.
238. Braak H, Braak E, Bohl J, Lang W. Alzheimer's disease: amyloid plaques in the cerebellum. J Neurol Sci 1989; 93: 277-87.
239. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellumin Alzheimer's disease. Am J Pathol 1989; 135: 309-19.
240. Dickson DW, Wertkin A, Mattiace LA, et al. Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease. Acta Neuropathol 1990; 79: 486-93.
241. Fukutani Y, Cairns NJ, Rossor MN, Lantos PL. Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease. Neurosci Lett 1996; 214: 33-6.
242. Koyama A, O'Brien J, Weuve J, et al. The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J Gerontol A Biol Sci Med Sci 2013; 68: 433-40.
243. Guo JT, Yu J, Grass D, de Beer FC, Kindy MS. Inflammationdependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J Neurosci 2002; 22: 5900-9.
244. Lee JW, Lee YK, Yuk DY, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 2008; 5: 37.
245. Hirose Y, Imai Y, Nakajima K, et al. Glial conditioned medium alters the expression of amyloid precursor protein in SH-SY5Y neuroblastoma cells. Biochem Biophys Res Commun 1994; 198: 504-9.
246. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992; 89: 10075-8.
247. Sastre M, Dewachter I, Landreth GE, et al. Nonsteroidal antiinflammatory drugs and peroxisome proliferator-activated receptorgamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003; 23: 9796-804.
248. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13: 63-8.
249. Frings L, Spehl TS, Weber WA, Hüll M, Meyer PT. Amyloid-β Load Predicts Medial Temporal Lobe Dysfunction in Alzheimer Dementia. J Nucl Med 2013; 54: 1909-14.
250. Rodríguez JJ, Noristani HN, Hilditch T, Olabarria M, Yeh CY, Witton J, Verkhratsky A. Increased densities of resting and activated microglia in the dentate gyrus follow senile plaque formation in the CA1 subfield of the hippocampus in the triple transgenic modelof Alzheimer's disease. Neurosci Lett 2013; 552: 129-34.
251. Jaworski T, Lechat B, Demedts D, et al. Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration. Am J Pathol 2011; 179: 2001-15.
252. Wright AL, Zinn R, Hohensinn B, et al. Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS One 2013; 8: e59586.
253. Kahn MS, Kranjac D, Alonzo CA, et al. Prolonged elevation in hippocampal Aβ and cognitive deficits following repeated endotoxin exposure in the mouse. Behav Brain Res 2012; 229: 176-84.
254. Bossù P, Cutuli D, Palladino I, et al. A single intraperitoneal injection of endotoxin in rats induces long-lasting modifications in behavior and brain protein levels of TNF-α and IL-18. J Neuroinflammation 2012; 9: 101.
255. Moore AH, Wu M, Shaftel SS, Graham KA, O'Banion MK. Sustained expression of interleukin-1beta in mouse hippocampus impairs spatial memory. Neuroscience 2009; 164: 1484-95.
256. Gasparini L, Rusconi L, Xu H, del Soldato P, Ongini E. Modulation of beta-amyloid metabolism by non-steroidal antiinflammatory drugs in neuronal cell cultures. J Neurochem 2004; 88: 337-48.
257. Shaw KN, Commins S, O'Mara SM. Lipopolysaccharide causes deficits in spatial learning in the water maze but not in BDNF expression in the rat dentate gyrus. Behav Brain Res 2001; 124: 47-54.
258. Sparkman NL, Martin LA, Calvert WS, Boehm GW. Effects of intraperitoneal lipopolysaccharide on Morris maze performance in year-old and 2-month-old female C57BL/6J mice. Behav Brain Res 2005; 159: 145-51.
259. Eikelenboom P, Zhan SS, Van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994; 15: 447-50.
260. Eikelenboom P, van Exel E, Hoozemans JJ, et al. Neuroinflammation-an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener Dis 2010; 7: 38-41.
261. Eikelenboom P, Veerhuis R, van Exel E, et al. The early involvement of the innate immunity in the pathogenesis of lateonset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 2011; 8: 142-50.
262. Eikelenboom P, Hoozemans JJ, Veerhuis R, et al. Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease. Alzheimers Res Ther 2012; 4: 15.
263. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 2010; 16: 2766-78.
264. Daulatzai MA. Early stages of pathogenesis in memory impairment during normal senescence and Alzheimer's disease. J Alzheimers Dis 2010; 20: 355-67.
265. Daulatzai MA. Conversion of Elderly to Alzheimer's Dementia: Role of Confluence of Hypothermia and Senescent stigmata-the Plausible Pathway. J Alzheimers Dis 2010; 21: 1039-63.
266. Daulatzai MA. Role of sensory stimulation in the amelioration of obstructive sleep apnea. Sleep Disord 2011; 2011: 596879.
267. Daulatzai MA. Memory and Cognitive Dysfunctions in Alzheimer's disease are Inextricably Intertwined with Neuroinflammation due to Aging, Obesity, Obstructive Sleep Apnea, and other Upstream Risk Factors. In: Costa AA, Villalba E, Eds.; Horizons in Neuroscience Research. NY Nova Science Publishers Inc. 2012; pp. 69-106.
268. Daulatzai MA. Pathogenesis of Cognitive Dysfunction in Patients with Obstructive Sleep Apnea: A Hypothesis with Emphasis on the Nucleus Tractus Solitarius. Sleep Disord 2012; 2012: 251096.
269. Daulatzai MA. Neuroinflammation and Dysfunctional Nucleus Tractus Solitarius: Their Role in Neuropathogenesis of Alzheimer's Dementia. Neurochem Res 2012; 37: 846-68.
270. Daulatzai MA. Quintessential Risk Factors: Their Role in Promoting Cognitive Dysfunction and Alzheimer's disease. Neurochem Res 2012; 37: 2627-58.
271. Daulatzai MA. Death by a thousand cuts in Alzheimer's disease: hypoxia: the prodrome. Neurotox Res 2013; 24: 216-43.
272. Daulatzai MA. Neurotoxic Saboteurs: Straws that Break the Hippo's (Hippocampus) Back drive Cognitive Impairment and Alzheimer's disease. Neurotox Res 2013; 24: 407-59.
273. Turrin NP, Gayle D, Ilyin SE, et al. Pro-inflammatory and antiinflammatory cytokine mRNA induction in the peripheryand brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res Bull 2001; 54: 443-53.
274. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res 2010; 33: 1539-56.
275. Cerejeira J, Firmino H, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. Acta Neuropathol 2010; 119: 737-54.
276. Cunningham C. Systemic inflammation and delirium: important cofactors in the progression of dementia. Biochem Soc Trans 2011; 39: 945-53.
277. Cunningham C, MacLullich AMJ. At the extreme end of the psychoneuroimmunological spectrum: Delirium as a maladaptive sickness behaviour response. Brain Behavior Immunity 2013; 28: 1-13.
278. Murray C, Sanderson DJ, Barkus C, et al. Systemic inflammation induces acute working memory deficits in the primed brain: Relevance for delirium. Neurobiol Aging 2012; 33: 603-16.
279. Koloski N-A, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J Gastroenterol 2008; 14: 165-73.
280. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 2010; 6: 339-46.
281. Saei AA, Barzegari A. The microbiome: the forgotten organ of the astronaut's body-probiotics beyond terrestrial limits. Fut Microbiol 2012; 7: 1037-46.
282. Frolkis A, Dieleman LA, Barkema HW, et al. Environment and the inflammatory bowel diseases. Can J Gastroenterol 2013; 27: e18-24.
283. Foster A, Jacobson K. Changing incidence of inflammatory bowel disease: Environmental influences and lessons learnt from the South Asian population. Front Pediatr 2013; 1: 34.
284. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 2008; 57: 1185-91.
285. Shanahan F, Bernstein CN. The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol 2009; 25: 301-5.
286. Gent AE, Hellier MD, Grace RH, Swarbrick ET, Coggon D. Inflammatory bowel disease and domestic hygiene in infancy. Lancet 1994; 343: 766-7.
287. Card T, Logan RFA, Rodrigues LC, Wheeler JG. Antibiotic use and the development of Crohn's disease. Gut 2004; 53: 246-50.
288. Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol 1987; 22: 1009-24.
289. Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn's disease. Scand J Gastroenterol 2008; 43: 961-6.
290. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 2005; 54: 1481-91.
291. Lerebours E, Gower-Rousseau C, Merle V, et al. Stressful life events as a risk factor for inflammatory bowel disease onset: A population-based case-control study. Am J Gastroenterol 2007; 102: 122-31.
292. Mazzon E, Sturniolo GC, Puzzolo D, Frisina N, Fries W. Effect of stress on the paracellular barrier in the rat ileum. Gut 2002; 51: 507-13.
293. Soderholm JD, Yang P-C, Ceponis P, et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 2002; 123: 1099-108.
294. Kaplan GG, Szyszkowicz M, Fichna J, et al. Non-specific abdominal pain and air pollution: a novel association. PLoS One 2012; 7: e47669.
295. Krajmalnik-Brown R, Ilhan ZE, Kang DW, DiBaise JK. Effects of gut microbes on nutrient absorption and energy regulation. Nutr Clin Pract 2012; 27: 201-14.
296. Guzman JR, Conlin VS, Jobin C. Diet, microbiome, and the intestinal epithelium: an essential triumvirate? Biomed Res Int 2013; 2013: 425146.
297. Tsai F, Coyle WJ. The microbiome and obesity: is obesity linked to our gut flora? Curr Gastroenterol Rep 2009; 11: 307-13.
298. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-20.
299. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-3.
300. Laugerette F, Vors C, Peretti N, Michalski MC. Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. Biochimie 2011; 93: 39-45.
301. Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286-92.
302. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63.
303. Karlsson FH, Fåk F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012; 3: 1245.
304. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-88.
305. Erion JR, Wosiski-Kuhn M, Dey A, et al. Obesity elicits interleukin 1-mediated deficits in hippocampal synaptic plasticity. J Neurosci 2014; 34: 2618-31.
306. Daulatzai MA. Obesity and Gut's Dysbiosis Promote Neuroinflammation, Cognitive Impairment, and Vulnerability to Alzheimer's disease: New Directions and Therapeutic Implications. J Mol Genet Med 2014; S1: 005.
307. Elin RJ, Wolff SM. Biology of endotoxin. Annu Rev Med 1976; 27: 127-41.
308. Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma 2000; 17: 871-90.
309. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-72.
310. Wong SW, Kwon MJ, Choi AM, et al. Fatty acids modulate Tolllike receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J Biol Chem 2009; 284: 27384-92.
311. Roth TL, Nayak D, Atanasijevic T, et al. Transcranial amelioration of inflammation and cell death after brain injury. Nature 2014; 505: 223-8.
312. Priyanka A, Anusree SS, Nisha VM, Raghu KG. Curcumin improves hypoxia induced dysfunctions in 3T3-L1 adipocytes by protecting mitochondria and down regulating inflammation. Biofactors 2014; 40(5): 513-23.
313. Czeh M, Gressens P, Kaindl AM. The yin and yang of microglia. Dev Neurosci 2011; 33: 199-209.
314. Nishikawa T, Naruse K, Kobayashi Y, et al. Involvement of nitrosative stress in experimental periodontitis in diabetic rats. J Clin Periodontol 2012; 39: 342-9.
315. Kim YC, Park TY, Baik E, Lee SH. Fructose-1, 6-bisphosphate attenuates induction of nitric oxide synthase in microglia stimulated with lipopolysaccharide. Life Sci 2012; 90: 365-72.
316. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-95.
317. Maracchioni A, Totaro A, Angelini DF, et al. Mitochondrial damage modulates alternative splicing in neuronal cells: implications for neurodegeneration. J Neurochem 2007; 100: 142-53.
318. Buizza L, Cenini G, Lanni C, et al. Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease. PLoS One 2012; 7: e29789.
319. Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32: 1139-51.
320. Robinson KA, Stewart CA, Pye QN, et al. Redox-sensitive protein phosphatase activity regulates the phosphorylation state of p38 protein kinase in primary astrocyte culture. J Neurosci Res 1999; 55: 724-32.
321. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009; 9: 429-39.
322. Kim SH, Johnson VJ, Shin TY, Sharma RP. Selenium attenuates lipopolysaccharide-induced oxidative stress response through modulation of p38 MAPK and NF-kB signaling pathways. Exp Biol Med 2004; 229: 203-13.
323. Pawate S, Shen Q, Fan F, Bhat N. Redox regulation of glial inflammatory response to lipopolysaccharide and interferon. J Neurosci Res 2004; 77: 540-51.
324. Riikonen J, Jaatinen P, Rintala J, et al. Intermittent ethanol exposure increases the number of cerebellar microglia. Alcohol Alcohol 2002; 37: 421-6.
325. Potula R, Haorah J, Knipe B, et al. Alcohol abuse enhances neuroinflammation and impairs immune responses in an animal model of human immunodeficiency virus-1 encephalitis. Am J Pathol 2006; 168: 1335-44.
326. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010; 6: 193-201.
327. Gelderblom M, Leypoldt F, Steinbach K, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009; 40: 1849-57.
328. Lowes DA, Thottakam BM, Webster NR, Murphy MP, Galley HF. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic Biol Med 2008; 45: 1559-65.
329. Dashdorj A, Jyothi KR, Lim S, et al. Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines. BMC Med 2013; 11: 178.
330. Wang A, Keita AV, Phan V, et al. Targeting Mitochondria-Derived Reactive Oxygen Species to Reduce Epithelial Barrier Dysfunction and Colitis. Am J Pathol 2014; 14: 00321-6.
331. Xing B, Xin T, Hunter RL, Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation 2008; 5: 4.
332. Carta AR, Pisanu A. Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease? Neurotox Res 2013; 23: 112-23.
333. Wani WY, Gudup S, Sunkaria A, et al. Protective efficacy of mitochondrial targeted antioxidant MitoQ against dichlorvos induced oxidative stress and cell death in rat brain. Neuropharmacology 2011; 61: 1193-201.
334. Rump TJ, Abdul Muneer PM, Szlachetka AM, et al. Acetyl-Lcarnitine protects neuronal function from alcohol-induced oxidative damage in the brain. Free Radic Biol 2010; 49: 1494-504.
335. Haorah J, Floreani NA, Knipe B, Persidsky Y. Stabilization of superoxide dismutase by acetyl-l-carnitine in human brain endothelium during alcohol exposure: novel protective approach. Free Radic Biol Med 2011; 51: 1601-9.
336. Wang JY, Wen LL, Huang YN, Chen YT, Ku MC. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of gliamediated inflammation. Curr Pharm Des 2006; 12: 3521-33.
337. Qin L, Crews FT. NADPH oxidase and reactive oxygen species contribute to alcohol-induced microglial activation and neurodegeneration. J Neuroinflammation 2012; 9: 5.
338. Cunningham C. Microglia and neurodegeneration: the role of systemic inflammation. Glia 2013; 61: 71-90.
339. Sakurai T, Kudo M, Watanabe T, et al. Hypothermia protects against fulminant hepatitis in mice by reducing reactive oxygen species production. Dig Dis 2013; 31: 440-6.
340. Lee YJ, Choi DY, Yun YP, et al. Ethanol extract of Magnolia officinalis prevents lipopolysaccharide-induced memory deficiency via its antineuroinflammatory and antiamyloidogenic effects. Phytother Res 2013; 27: 438-47.
341. Henry CJ, Huang Y, Wynne A, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 2008; 5: 15.
342. Meador JP, Caldwell ME, Cohen PS, Conway T. Escherichia coli pathotypes occupy distinct niches in the mouse intestine. Infect Immun 2014; 82: 1931-8.
343. Kamada N, Grace Chen G, Núñez G. A complex microworld in the gut: Harnessing pathogen-commensal relations. Nat Med 2012; 18: 1190-1.
344. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 2011; 108: 16050-5.
345. Christmas D, Steele JD, Tolomeo S, Eljamel MS, Matthews K. Vagus nerve stimulation for chronic major depressive disorder: 12-month outcomes in highly treatment-refractory patients. J Affect Disord 2013; 150: 1221-5.
346. Marras CE, Chiesa V, De Benedictis A, et al. Vagus nerve stimulation in refractory epilepsy: New indications and outcome assessment. Epilepsy Behav 2013; 28: 374-8.
347. Chen C, Zhang Y, Du Z, et al. Vagal Efferent Fiber Stimulation Ameliorates Pulmonary Microvascular Endothelial Cell Injury by Downregulating Inflammatory Responses. Inflammation 2013; 36: 1567-75.
348. Hamann JJ, Ruble SB, Stolen C, et al. Vagus nerve stimulation improves left ventricular function in a canine model of chronic heart failure. Eur J Heart Fail 2013; 15: 1319-26.
349. Zhang Y, Popovic ZB, Bibevski S, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2009; 2: 692-9.
350. Zhou H, Liang H, Li ZF, et al. Vagus Nerve Stimulation Attenuates Intestinal Epithelial Tight Junctions Disruption in Endotoxemic Mice Through α7 Nicotinic Acetylcholine Receptors. Shock 2013; 40: 144-51.
351. Zhang Y, Ilsar I, Sabbah HN, Ben David T, Mazgalev TN. Relationship between right cervical vagus nerve stimulation and atrial fibrillation inducibility: therapeutic intensities do not increase arrhythmogenesis. Heart Rhythm 2009; 6: 244-50.
352. He W, Jing X, Wang X, et al. Transcutaneous auricular vagus nerve stimulation as a complementary therapy for pediatric epilepsy: A pilot trial. Epilepsy Behav 2013; 28: 343-6.
353. Dunn AJ, Berridge CW. Physiological and behavioral-responses to corticotropin-releasing factor administration-is Crf a mediator of anxiety or stress responses. Brain Res Rev 1990; 15: 71-100.
354. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213: 1394-7.
355. Heim C, Nemeroff CB. Neurobiology of posttraumatic stress disorder. CNS Spectrums 2009; 14: 13-24.
356. Fukudo S. Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol 2007; 42: 48-51.
357. Stahl SM, Wise DD. The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders. CNS Spectrums 2008; 13: 467-72.
358. Taché Y, Kiank C, Stengel A. A role for corticotropin-releasing factor in functional gastrointestinal disorders. Curr Gastroenterol Rep 2009; 11: 270-7.
359. Labus JS, Hubbard CS, Bueller J, et al. Impaired emotional learning and involvement of the corticotropin-releasing factor signaling system in patients with irritable bowel syndrome. Gastroenterology 2013; 145: 1253-61.
360. Hubbard CS, Labus JS, Bueller J, et al. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. J Neurosci 2011; 31: 12491-500.
361. Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut 2000; 47: 861-9.
362. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
363. Martinez V, Taché Y. CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 2006; 12: 4071-88.
364. Phelps EA, O'Connor KJ, Gatenby JC, et al. Activation of the left amygdala to a cognitive representation of fear. Nat Neurosci 2001; 4: 437-41.
365. Simpson JR, Drevets WC, Snyder AZ, Gusnard DA, Raichle ME. Emotion-induced changes in human medial prefrontal cortex: II. During anticipatory anxiety. Proc Natl Acad Sci USA 2001; 98: 688-93.
366. Straube T, Schmidt S, Weiss T, Mentzel HJ, Miltner WHR. Dynamic activation of the anterior cingulate cortex during anticipatory anxiety. Neuroimage 2009; 44: 975-81.
367. Taché Y, Martinez V, Wang L, Million M. CRF1 receptor signaling pathways are involvedin stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol 2004; 141: 1321-30.
368. Kawashima K, Fujii T, Moriwaki Y, Misawa H, Horiguchi K. Reconciling neuronally and nonneuronally derived acetylcholine in the regulation of immune function. Ann NY Acad Sci 2012; 1261: 7-17.
369. Rosas-Ballina M, Olofsson PS, Ochani M, et al. Acetylcholinesynthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011; 334: 98-01.
370. Pavlov VA, Parrish WR, Rosas-Ballina M, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun 2009: 23: 41-5.
371. Buccafusco JJ, Terry AV Jr. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol 2009; 78: 852-62.
372. Cannon CE, Puri V, Vivian JA, et al. The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys. Neuropharmacology 2013; 64: 191-6.
373. Bussière T, Giannakopoulos P, Bouras C, et al. Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: Stereologic analysis of prefrontal cortex area 9. J Comp Neurol 2003; 463: 281-302.
374. Mineur YS, Picciotto MR. Nicotine receptors and depression: Revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 2010; 31: 580-6.
375. Waki H, Gouraud SS, Maeda M, Raizada MK, Paton JF. Contributions of vascular inflammation in the brainstem for neurogenic hypertension. Respir Physiol Neurobiol 2011; 178: 422-8.
376. Paton JF, Waki H. Is neurogenic hypertension related to vascular inflammation of the brainstem? Neurosci Biobehav Rev 2009; 33: 89-94.
377. Plata-Salamán CR, Ilyin SE, Gayle D, Flynn MC. Gram-negative and gram-positive bacterial products induce differential cytokine profiles in the brain: analysis using an integrative molecularbehavioral in vivo model. Int J Mol Med 1998; 1: 387-97.
378. Volta U, Corazza GR, Frisoni M, et al. IgA antigliadin antibodies and persistence of jejunal lesions in adult coeliac disease. Digestion 1990; 47: 111-4.